The Development of a European Registry for Facial Dysostosis Syndromes: A Delphi-Guided Approach

Altres autors/es

Institut Català de la Salut

[van Roey VL, Ombashi S, Mathijssen I, Bouzariouh A] European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose, and Throat Disorders, Rotterdam, The Netherlands. Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands. [Munkhammar AA] European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose, and Throat Disorders, Rotterdam, The Netherlands. Uppsala University Hospital, Uppsala, Sweden. [Åsten PM] European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose, and Throat Disorders, Rotterdam, The Netherlands. Oslo University Hospital, Oslo, Norway. [Munill Ferrer M] European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose, and Throat Disorders, Rotterdam, The Netherlands. Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2025-11-06T13:39:28Z

2025-11-06T13:39:28Z

2025-11



Resum

Acrofacial dysostosis; Delphi technique; Miller syndrome


Disostosis acrofacial; Técnica Delphi; Síndrome de Miller


Disostosi acrofacial; Tècnica Delphi; Síndrome de Miller


Craniosynostosis is a multigenic congenital condition in which one or more calvarial sutures have prematurely fused during the development of the fetus. Pathogenic variants in FGFR2 are associated with the development of syndromic craniosynostosis, such as Crouzon, Apert and Pfeifer syndromes. Investigation of FGFR2-linked craniosynostosis is hindered by the lack of appropriate in vitro models. Patient-derived human induced pluripotent stem cell (hiPSC) in vitro disease models provide the opportunity to investigate the disease, identify molecular targets for pharmaceutical treatments, and enable the generation of autologous pluripotent stem cell catalogues. Here, we report three patient-derived hiPSC lines carrying the C342Y, S252W or E565G FGFR2 pathogenic variant. The patient hiPSC lines express characteristic pluripotency markers and display distinct phosphorylation profiles under unstimulated conditions. FGFR2C342Y showed autophosphorylation in the absence of bFGF ligand, although downstream docking proteins PLCγ and FRS2α were not phosphorylated. FGFR2S252W and FGFR2E565G hiPSCs showed increased phosphorylation of docking proteins PLCγ and FRS2α, whereas FGFR2 was not phosphorylated. These patient hiPSC lines provide molecular and cellular options to investigate FGFR2-linked craniosynostosis in the patient-specific genomic context and develop therapeutic modalities.


The present study was partially funded by the European Reference Network for rare and/or complex craniofacial anomalies and ear, nose, and throat (ENT) disorders (ERN CRANIO) in terms of personnel costs of the first author. ERN CRANIO is funded by the European Union.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Wolters Kluwer Health

Documents relacionats

Journal of Craniofacial Surgery;36(8)

https://doi.org/10.1097/SCS.0000000000011695

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)